{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.69, "exchange": "FRA", "shortName": "AUTOLUS THERAP. SP.ADR/1", "longName": "Autolus Therapeutics plc", "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "marketState": "REGULAR", "esgPopulated": false, "priceEpsCurrentYear": -0.9494383, "sharesOutstanding": 173075008, "bookValue": 1.726, "fiftyDayAverage": 1.732, "fiftyDayAverageChange": -0.041999936, "fiftyDayAverageChangePercent": -0.024249386, "twoHundredDayAverage": 2.2367, "twoHundredDayAverageChange": -0.5467, "twoHundredDayAverageChangePercent": -0.24442258, "marketCap": 292496768, "forwardPE": -0.91847825, "priceToBook": 0.9791426, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1532930400000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683871451, "regularMarketDayHigh": 1.69, "regularMarketDayRange": "1.69 - 1.69", "regularMarketDayLow": 1.69, "regularMarketVolume": 50, "regularMarketPreviousClose": 1.69, "bid": 1.66, "ask": 1.69, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.69, "averageDailyVolume3Month": 295, "averageDailyVolume10Day": 20, "fiftyTwoWeekLowChange": 0.22000003, "fiftyTwoWeekLowChangePercent": 0.14965989, "fiftyTwoWeekRange": "1.47 - 3.64", "fiftyTwoWeekHighChange": -1.95, "fiftyTwoWeekHighChangePercent": -0.53571427, "fiftyTwoWeekLow": 1.47, "fiftyTwoWeekHigh": 3.64, "earningsTimestamp": 1683203400, "earningsTimestampStart": 1683203400, "earningsTimestampEnd": 1683203400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.47, "epsForward": -1.84, "epsCurrentYear": -1.78, "symbol": "6A3A.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "The MediaWorks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 399, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 2716222, "fmt": "2.72M", "longFmt": "2,716,222"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 50, "title": "Founder, Sr. VP & Chief Scientific Officer", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lucinda  Crabtree Ph.D.", "age": 42, "title": "Sr. VP & CFO", "yearBorn": 1980, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 57, "title": "Sr. VP & COO", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 66, "title": "Sr. VP & Chief Technical Officer", "yearBorn": 1956, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 56, "title": "Sr. VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Edgar E. W. Braendle M.D., Ph.D.", "age": 62, "title": "Sr. VP & Chief Devel. Officer", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Chris  Williams", "age": 42, "title": "Sr. VP of Corp. Devel.", "yearBorn": 1980, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "title": "Chief HR Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}